*Department of Medical Genetics, University of British Columbia;
†British Columbia Children's Hospital Research Institute;
‡Division of Pediatric Hematology/Oncology/Bone and Marrow Transplant, Department of Pediatrics, University of British Columbia;
§Department of Pharmaceutical Sciences, University of British Columbia; and
¶Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Correspondence: Bruce C. Carleton, PharmD, Division Head, Translational Therapeutics, Department of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada (e-mail: [email protected]).
The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is funded by the Canadian Institutes of Health Research (CIHR), Genome Canada, and Genome British Columbia with additional support provided by British Columbia's Provincial Health Services Authority (PHSA), BC Children's Hospital Foundation, Health Canada, and others.
The authors declare no conflict of interest.
Conceptualization: A. Siemens and B. C. Carleton; methodology: A. Siemens; data curation: A. Siemens; investigation: A. Siemens; formal analysis: A. Siemens; visualization: A. Siemens; writing—original draft preparation: A. Siemens; writing—review and editing: S. R. Rassekh, C. J. D. Ross, and B. C. Carleton; supervision: B. C. Carleton. All authors have read and agreed to the published version of the manuscript.
